Cohen Enterprises, Inc. acquires Mangoceuticals, Inc. (2022)

Deal facts

Buyer: Cohen Enterprises, Inc.
Target: Mangoceuticals, Inc.
Deal value: Not disclosed
Announced: 23 June 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

16 Jun 2022CompletedClosed
Cohen Enterprises, Inc. completes acquisition of Mangoceuticals, Inc.
Item 1.01 Entry into a Material Definitive Agreement. Mangoceuticals Sale On June 16, 2022, American International Holdings Corp. (the “ Company ”, “ we ” or “ us ”), entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “ SPA ”), with Cohen Enterprises, Inc. (“ Cohen Enterprises ”), which entity is owned and controlled by Jacob D. Cohen, the Chief Executive Offi
Source

OpinionExit Mode editorial

We see a straightforward strategic acquisition in the healthcare sector where Cohen Enterprises, Inc. has completed its purchase of Mangoceuticals, Inc. The deal was announced on 23 June 2022 and has since closed. Both parties are based in the United States, which simplifies the regulatory landscape compared to cross-border transactions involving the UK or EU. The entire consideration was paid in cash, a structure that removes the uncertainty often associated with earn-outs or share-based payments. For the SME founder reading this, the clarity of a cash deal is a significant advantage, as it provides immediate liquidity and a clean exit without ongoing performance contingencies.

The strategic nature of this transaction suggests that the buyer identified specific capabilities or market access within Mangoceuticals that complement its existing portfolio. In the healthcare industry, such acquisitions often aim to integrate new product lines or secure distribution channels rather than simply expanding financial scale. The absence of a disclosed value in public records is not uncommon for private company transactions, yet the completion status confirms that both sides agreed on terms that satisfied their respective due diligence requirements. This outcome highlights the importance of aligning strategic fit with commercial terms, ensuring that the buyer sees clear value in the target's operations beyond just the balance sheet.

Regulatory clearance in a domestic US healthcare deal typically involves standard antitrust review, but the lack of reported hurdles indicates the transaction likely fell below thresholds that would trigger a lengthy investigation by the Federal Trade Commission. For founders navigating similar paths, the speed of completion often correlates with the simplicity of the consideration structure and the absence of complex change-of-control covenants. We believe this deal serves as a practical example of how a pure cash offer can streamline negotiations and accelerate the path to closing, provided the strategic rationale is sound and the regulatory environment is permissive.

Your immediate action this week should be to audit your current customer contracts for any change-of-control clauses that could be triggered by a potential buyer's entry. Many founders overlook these provisions until a deal is imminent, only to find that third-party consent is required to complete the sale. Identify which agreements need early engagement and prepare a summary of your key commercial relationships to present to any prospective acquirer. This preparation will prevent last-minute delays and demonstrate operational maturity during the due diligence phase.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More strategic acquisition deals More from Cohen Enterprises, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 July 2026CompletedHealthcare

GSK plc to acquire Nuvalent, Inc

GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…

Buyer: GSK plc
Target: Nuvalent, Inc
Deal value: USD 10,600,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

14 July 2026CompletedHealthcare

Volex plc to acquire Kepler SignalTek Ltd

Volex plc has agreed to acquire Kepler SignalTek Ltd, a healthcare sector business based in the United Kingdom. The strategic acquisition was announced and completed on…

Buyer: Volex plc
Target: Kepler SignalTek Ltd
Deal value: USD 89,400,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

2 July 2026CompletedHealthcare

Lixte Biotechnology Holdings, Inc. to acquire Nomad Transportable Power Systems, Inc.

Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction…

Buyer: Lixte Biotechnology Holdings, Inc.
Target: Nomad Transportable Power Systems, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer: Public Company Management Corporation
Target: Physicians Capital Management Corporation
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history